SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
SELLAS Life Sciences announced that three preclinical studies evaluating their CDK9 inhibitor SLS009 in pancreatic ductal adenocarcinoma (PDAC) models will be presented at the 2026 AACR Conference. These studies, conducted in collaboration with University of Wisconsin, explore novel therapeutic approaches involving SLS009 alone and in combination, …